Connection

Co-Authors

This is a "connection" page, showing publications co-authored by YILING LU and HAN LIANG.
Connection Strength

2.906
  1. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.449
  2. A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies. Nat Cancer. 2024 Oct; 5(10):1579-1595.
    View in: PubMed
    Score: 0.246
  3. Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell. 2022 11 14; 40(11):1324-1340.e8.
    View in: PubMed
    Score: 0.217
  4. A functional genomic approach to actionable gene fusions for precision oncology. Sci Adv. 2022 02 11; 8(6):eabm2382.
    View in: PubMed
    Score: 0.206
  5. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
    View in: PubMed
    Score: 0.189
  6. TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. Mol Cell Proteomics. 2019 08 09; 18(8 suppl 1):S15-S25.
    View in: PubMed
    Score: 0.172
  7. Analytical Platforms 3: Processing Samples via the RPPA Pipeline to Generate Large-Scale Data for Clinical Studies. Adv Exp Med Biol. 2019; 1188:113-147.
    View in: PubMed
    Score: 0.166
  8. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res. 2017 11 01; 77(21):e51-e54.
    View in: PubMed
    Score: 0.153
  9. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125.
    View in: PubMed
    Score: 0.148
  10. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239.
    View in: PubMed
    Score: 0.146
  11. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):515-528.
    View in: PubMed
    Score: 0.133
  12. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res. 2016 Jan 15; 22(2):513-23.
    View in: PubMed
    Score: 0.131
  13. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
    View in: PubMed
    Score: 0.116
  14. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Nov; 10(11):1046-7.
    View in: PubMed
    Score: 0.115
  15. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012 Nov; 22(11):2120-9.
    View in: PubMed
    Score: 0.108
  16. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. 2020 07; 8(7):952-965.
    View in: PubMed
    Score: 0.045
  17. A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. Cancer Cell. 2018 05 14; 33(5):817-828.e7.
    View in: PubMed
    Score: 0.040
  18. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018 03 12; 33(3):450-462.e10.
    View in: PubMed
    Score: 0.039
  19. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014 Oct 13; 26(4):479-94.
    View in: PubMed
    Score: 0.031
  20. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29; 5:3887.
    View in: PubMed
    Score: 0.030
  21. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 Jul; 1(2):170-85.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.